tm
Seeing Is Believing
tm
Seeing Is Believing
LCTX is currently covered by 3 analysts with an average price target of $5.33. This is a potential upside of $4.38 (461.05%) from yesterday's end of day stock price of $0.95.
Lineage Cell Therapeutics's activity chart (see below) currently has 32 price targets and 42 ratings on display. The stock rating distribution of LCTX is 100% BUY.
Highest price target for LCTX is $9, Lowest price target is $3, average price target is $5.33.
Most recent stock forecast was given by JASON KOLBERT from D. BORAL CAPITAL on 04-May-2026. First documented stock forecast 08-Feb-2021.
Currently out of the existing stock ratings of LCTX, 7 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Mar-2022
$3
$1.97 (191.26%)
$3
5 months 18 days ago
(04-May-2026)
0/13 (0%)
$1.58 (111.27%)
Buy Since 14-Jun-2022
$4
$2.97 (288.35%)
6 months 27 days ago
(25-Mar-2026)
0/4 (0%)
$2.45 (158.06%)
Buy Since 24-Jul-2023
$9
$7.97 (773.79%)
$9
6 months 28 days ago
(24-Mar-2026)
0/6 (0%)
$7.52 (508.11%)
Buy Since 02-Nov-2022
$5
$3.97 (385.44%)
$5
1 years 29 days ago
(23-Sep-2025)
0/3 (0%)
$3.41 (214.47%)
Buy Since 08-Feb-2021
$3
$1.97 (191.26%)
$5
1 years 2 months 17 days ago
(05-Aug-2025)
0/3 (0%)
$2.04 (212.50%)
Which analyst most recently updated their price target on LCTX (Lineage Cell Therapeutics)?
Which analyst has the most public recommendations on LCTX (Lineage Cell Therapeutics)?
Which analyst is the currently most bullish on LCTX (Lineage Cell Therapeutics)?
Which analyst is the currently most reserved on LCTX (Lineage Cell Therapeutics)?
